PTC Therapeutics, Inc. (PTCT)

Market Cap	5.46B +41.5%
Revenue (ttm)	1.73B +114.5%
Net Income	682.64M
EPS	7.78
Shares Out	82.77M
PE Ratio	8.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	247,508
Open	67.91
Previous Close	68.56
Day's Range	65.50 - 68.12
52-Week Range	35.95 - 87.50
Beta	0.56
Analysts	Buy
Price Target	80.94 (+22.75%)
Earnings Date	Feb 19, 2026

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 991
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT
• Website: https://www.ptcbio.com

Analyst Summary

According to 16 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $80.94, which is an increase of 22.75% from the latest price.

Price Target

$80.94

(22.75% upside)

Analyst Consensus: Buy